Fibrinogen-Derived γ^377–395 Peptide Improves Cognitive Performance and Reduces Amyloid-β Deposition, without Altering Inflammation, in AβPP/PS1 Mice

Article type: Research Article

Authors: Aso, Ester^{a; b} | Serrano, Antonio L.^{b; c} | Muñoz-Cánoves, Pura^{b; c; d} | Ferrer, Isidro^{a; b; *}

Affiliations: [a] Institut de Neuropatologia, Servei d’Anatomia Patològica, IDIBELL-Hospital Universitari de Bellvitge, Universitat de Barcelona, L’Hospitalet de Llobregat, Spain | [b] CIBERNED, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Instituto Carlos III, Spain | [c] Cell Biology Group, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain | [d] Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

Correspondence: [*] Correspondence to: Isidro Ferrer, Institut de Neuropatologia, Servei d’Anatomia Patològica, IDIBELL-Hospital Universitari de Bellvitge, C/Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat, Spain. Tel.: +34 93 2607452; Fax: +34 93 2607503; 8082ifa@gmail.com

Abstract: Fibrinogen has emerged as a promising therapeutic target against Alzheimer’s disease because of its dual role in altered vascular function and amyloid-β aggregation. Here we provide evidence regarding cognitive improvement and reduction of brain parenchyma amyloid-β deposition in AβPP/PS1 mice after treatment for one month with the fibrinogen-blocking peptide Fibγ377–395. No alteration in glial response or other neuroinflammatory markers was observed in the cortex of treated animals. Considering these results and the fact that Fibγ377–395 does not affect coagulation function, this peptide could be considered as a promising and safe candidate for chronic treatment of Alzheimer’s disease.

Keywords: AβPP/PS1 mice, Alzheimer’s disease, amyloid, fibrinogen, inflammation

DOI: 10.3233/JAD-142928

Journal: Journal of Alzheimer's Disease, vol. 47, no. 2, pp. 403-412, 2015